Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated:  1/13/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated: 1/13/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated:  1/13/2016
Clinical Research Facility
mi
from
Columbus, OH
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated: 1/13/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated:  1/13/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated: 1/13/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated:  1/13/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated: 1/13/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated:  1/13/2016
Clinical Research Facility
mi
from
Nashville, TN
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated: 1/13/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated:  1/13/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated: 1/13/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated:  1/13/2016
Clinical Research Facility
mi
from
Houston, TX
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated: 1/13/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated:  1/13/2016
Clinical Research Facility
mi
from
La Crosse, WI
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated: 1/13/2016
Clinical Research Facility
mi
from
La Crosse, WI
Click here to add this to my saved trials
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated:  1/13/2016
mi
from
Randwick,
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects
A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Status: Enrolling
Updated: 1/13/2016
mi
from
Randwick,
Click here to add this to my saved trials
Smoking Cessation in Women With Gynecological Conditions
Immediate Smoking Cessation for Patients at Risk for Cervical Dysplasia, Cervical Cancer and Lower Genital Tract Dysplasia and Cancer - A Feasibility Study Comparing Nicotine Replacement Therapy With the Electronic Nicotine Delivery System.
Status: Enrolling
Updated:  1/13/2016
Stephenson Cancer Center
mi
from
Oklahoma City, OK
Smoking Cessation in Women With Gynecological Conditions
Immediate Smoking Cessation for Patients at Risk for Cervical Dysplasia, Cervical Cancer and Lower Genital Tract Dysplasia and Cancer - A Feasibility Study Comparing Nicotine Replacement Therapy With the Electronic Nicotine Delivery System.
Status: Enrolling
Updated: 1/13/2016
Stephenson Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Teramana Cancer Center
mi
from
Steubenville, OH
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Teramana Cancer Center
mi
from
Steubenville, OH
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Beaver
mi
from
Beaver, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Beaver
mi
from
Beaver, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Jefferson
mi
from
Clairton, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Jefferson
mi
from
Clairton, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Arnold Palmer at Mountain View
mi
from
Greensburg, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Arnold Palmer at Mountain View
mi
from
Greensburg, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Arnold Palmer at Oakbrook
mi
from
Greensburg, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Arnold Palmer at Oakbrook
mi
from
Greensburg, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Indiana
mi
from
Indiana, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Indiana
mi
from
Indiana, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Johnstown
mi
from
Johnstown, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Johnstown
mi
from
Johnstown, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
Hematology-Oncology Associates of UPCI
mi
from
McKeesport, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
Hematology-Oncology Associates of UPCI
mi
from
McKeesport, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
Hematology/Oncology - Private Practice
mi
from
McKeesport, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
Hematology/Oncology - Private Practice
mi
from
McKeesport, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Monroeville
mi
from
Monroeville, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Monroeville
mi
from
Monroeville, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Arnold Palmer at Mt. Pleasant
mi
from
Mt. Pleasant, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Arnold Palmer at Mt. Pleasant
mi
from
Mt. Pleasant, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - New Castle
mi
from
New Castle, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - New Castle
mi
from
New Castle, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - St. Margaret's
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - St. Margaret's
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers, Hillman Cancer Center
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers, Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Passavant
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Passavant
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
VA Healthcare System - 646
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
VA Healthcare System - 646
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Drake
mi
from
Pittsburgh, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Drake
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Uniontown
mi
from
Uniontown, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Uniontown
mi
from
Uniontown, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Washington
mi
from
Washington, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Washington
mi
from
Washington, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - North Hills
mi
from
Wexford, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - North Hills
mi
from
Wexford, PA
Click here to add this to my saved trials
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/13/2016
UPMC Cancer Centers - Windber
mi
from
Windber, PA
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/13/2016
UPMC Cancer Centers - Windber
mi
from
Windber, PA
Click here to add this to my saved trials
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)
Status: Enrolling
Updated:  1/14/2016
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)
Status: Enrolling
Updated: 1/14/2016
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
HD Melphalan and SCT in Patients With IGDD or LCDD
High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT) in Light-Chain Deposition Disease (LCDD) and Immunoglobulin Deposition Disease (IGDD)
Status: Enrolling
Updated:  1/14/2016
Boston University Cancer Research Center
mi
from
Boston, MA
HD Melphalan and SCT in Patients With IGDD or LCDD
High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT) in Light-Chain Deposition Disease (LCDD) and Immunoglobulin Deposition Disease (IGDD)
Status: Enrolling
Updated: 1/14/2016
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
A Phase II Study of Clofarabine and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Persistent Disease After Treatment With an Anthracycline and Cytarabine
Status: Enrolling
Updated:  1/14/2016
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
A Phase II Study of Clofarabine and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Persistent Disease After Treatment With an Anthracycline and Cytarabine
Status: Enrolling
Updated: 1/14/2016
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis
Status: Enrolling
Updated:  1/14/2016
Boston University Cancer Research Center
mi
from
Boston, MA
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis
Status: Enrolling
Updated: 1/14/2016
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
Phase 2 Study of Bortezomib (Velcade) for the Treatment of Steroid Refractory Chronic Graft-vs-Host Disease
Status: Enrolling
Updated:  1/15/2016
Charles A. Cancer Center, Baylor University Medical Center
mi
from
Dallas, TX
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
Phase 2 Study of Bortezomib (Velcade) for the Treatment of Steroid Refractory Chronic Graft-vs-Host Disease
Status: Enrolling
Updated: 1/15/2016
Charles A. Cancer Center, Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
Diet, Exercise and Estrogen Metabolites Study (DEEM)
Status: Enrolling
Updated:  1/15/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
Diet, Exercise and Estrogen Metabolites Study (DEEM)
Status: Enrolling
Updated: 1/15/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Status: Enrolling
Updated:  1/19/2016
Childrens National Medical Center
mi
from
Washington,
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Status: Enrolling
Updated: 1/19/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Status: Enrolling
Updated:  1/19/2016
University of California at San Francisco
mi
from
San Francisco, CA
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Status: Enrolling
Updated: 1/19/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Status: Enrolling
Updated:  1/19/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Status: Enrolling
Updated: 1/19/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Status: Enrolling
Updated:  1/19/2016
Hôpital Necker-Enfants Malades
mi
from
Paris,
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Status: Enrolling
Updated: 1/19/2016
Hôpital Necker-Enfants Malades
mi
from
Paris,
Click here to add this to my saved trials
Therapy of Early Chronic Phase CML With Gleevec
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571)
Status: Enrolling
Updated:  1/19/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Therapy of Early Chronic Phase CML With Gleevec
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571)
Status: Enrolling
Updated: 1/19/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Status: Enrolling
Updated:  1/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Status: Enrolling
Updated: 1/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration
Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration
Status: Enrolling
Updated:  1/20/2016
The Mayo Clinic
mi
from
Rochester, MN
Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration
Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration
Status: Enrolling
Updated: 1/20/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids
Weekly Subcutaneous Efalizumab for the Treatment of Steroid Refractory Graft-Versus-Host Disease of the Skin and Liver
Status: Enrolling
Updated:  1/20/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids
Weekly Subcutaneous Efalizumab for the Treatment of Steroid Refractory Graft-Versus-Host Disease of the Skin and Liver
Status: Enrolling
Updated: 1/20/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
City of Hope National Medical Center
mi
from
Duate, CA
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
City of Hope National Medical Center
mi
from
Duate, CA
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Stanford Comprehensive Cancer Center
mi
from
Stanford, CA
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Stanford Comprehensive Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Medical College of Georgia
mi
from
Augusta, GA
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Medical College of Georgia
mi
from
Augusta, GA
Click here to add this to my saved trials